Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Eksterne analyser

Bioextrax: Facilitating advances in client projects - VH Corp

Bioextrax

Dette er en ekstern analyse og afspejler ikke nødvendigvis vores perspektiv eller værdier.

Download analyse (PDF)
* EU proposes measures targeting microplastic pollution
* Enhanced cost control
* Our model implies a fair valuation of SEK 10.5 per share

During the third quarter, Bioextrax reached a commercial milestone when the American licensee exercised its option to advance in the existing licensing agreement. The licensee will be able to produce up to 1,000 tons of PHA annually starting from October 2023. In summary, the Q3 figures led to minor changes in our model. We maintain our fair value of SEK 10.5 per share. Looking ahead, we continue to expect some of the current customer discussions to materialise into term sheets. We see this as crucial to support our valuation.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team